[Post licensure safety surveillance for Prevenar]

Area of Science:

• Pharmacovigilance and vaccine safety monitoring.
• Pediatric infectious disease and immunization.
• Drug regulatory affairs and post-marketing surveillance.

Context:

• A pharmacovigilance survey was mandated by the French drug agency to monitor adverse effects of the Prevenar vaccine.
• The study focused on detecting rare, severe, or unexpected adverse events associated with the vaccine.
• Two reporting methods, systematic and spontaneous, were employed to capture adverse event data.

Purpose:

• To promptly identify and analyze rare, severe, or unexpected adverse effects (AEs) of the Prevenar vaccine.
• To fulfill a pharmacovigilance requirement set by the French drug agency (Afssaps).
• To compare findings with existing North American data (VAERS).

Summary:

• Over 19 months of intensive monitoring, 24 severe or unexpected AEs were reported, with fever and neurological manifestations being common.
• A longer period of spontaneous reporting identified 130 AEs, primarily fever, cutaneous, and neurological issues.
• Reported AEs, including fever, cutaneous, and neurological manifestations, were generally consistent with North American data.

Impact:

• Identified specific adverse events such as abnormal crying, member hypertonia, and vasculitis not previously listed in the Prevenar product information.
• The benefit-risk balance of the Prevenar vaccine remains favorable for protecting children against invasive pneumococcal infections.
• Provides crucial data for updating vaccine safety profiles and informing healthcare professionals and regulatory bodies.